LONDON—GlaxoSmithKline PLC has scored a minor victory in the battle to keep sales of its $9 billion-a-year asthma treatment Advair from being lost to generic competitors. . The company has obtained a preliminary injunction to prevent Sandoz—the generic-drug division of Novartis AG—from selling its rival inhaler AirFluSal Forspiro in Germany, because of its color. The Cologne regional court made the ruling.. Sandoz...
  